# Luye Pharma Group Ltd. clinical trials: 74 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 74 trials with Luye Pharma Group Ltd. as lead sponsor, 11 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Luye Pharma Group Ltd.: 74 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/luye-pharma-group-ltd

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 74
- Recruiting or not yet: 11
- Read on: November 19, 2026

## Trials

The 25 newest of 74, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| June 26, 2026 | NCT07671833 | A Study of LY03015 in Healthy Chinese and Caucasian Adult Subjects | Luye Pharma Group Ltd. | Phase 1 | Completed | Healthy Participants | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07671833) |
| April 8, 2026 | NCT07516899 | Mass Balance Study of \[14C\] LPM3770164 in Healthy Participants | Luye Pharma Group Ltd. | Phase 1 | Not yet recruiting | Huntington Disease | 8 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07516899) |
| February 9, 2026 | NCT07396870 | A Phase 2 Study to Evaluate the Efficacy and Safety of LY03020 in Acutely Psychotic Participants With Schizophrenia | Luye Pharma Group Ltd. | Phase 2 | Not yet recruiting | Schizophrenia | 160 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07396870) |
| February 6, 2026 | NCT07391566 | LPM6690176 in Combination With Chemotherapy and Bevacizumab in Metastatic Colorectal Cancer Patients With RAS Mutation | Luye Pharma Group Ltd. | Phase 1/2 | Not yet recruiting | Metastatic Colorectal Cancer (mCRC) | 99 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07391566) |
| January 27, 2026 | NCT07371065 | To Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Food Effects of LY03021 in Healthy Chinese Subjects | Luye Pharma Group Ltd. | Phase 1 | Enrolling by invitation | Major Depressive Disorder | 98 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07371065) |
| December 18, 2025 | NCT07292233 | A Food Effect Study of LY03020 in Healthy Subjects | Luye Pharma Group Ltd. | Phase 1 | Active not recruiting | Schizophrenia, Alzheimer's Disease Psychosis | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07292233) |
| November 19, 2025 | NCT07236476 | Identify Effective Doses of LY01021 in Controlled Ovarian Hyperstimulation (COH) for Female Subjects Undergoing Assisted Reproductive... | Luye Pharma Group Ltd. | Phase 2 | Active not recruiting | Assisted Reproduction | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07236476) |
| November 17, 2025 | NCT07230652 | A Phase 1 MAD Study to Evaluate the Safety and Tolerability of LY03020 | Luye Pharma Group Ltd. | Phase 1 | Recruiting | Schizophrenia, Alzheimer's Disease Psychosis | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07230652) |
| May 20, 2025 | NCT06980207 | A Phase 1, MAD Study to Evaluate the Safety, Tolerability and Pharmacokinetics of LY03017 | Luye Pharma Group Ltd. | Phase 1 | Not yet recruiting | Hallucinations and Delusions Associated With Alzheimer's Disease Psychosis, Hallucinations and Delusions Associated... | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06980207) |
| January 27, 2025 | NCT06793995 | Effect of Food and Age on the Pharmacokinetics of LY03017 | Luye Pharma Group Ltd. | Phase 1 | Not yet recruiting | Alzheimer's Disease Psychosis, Parkinson Disease Psychosis, Negative Symptoms of Schizophrenia | 26 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06793995) |
| December 12, 2024 | NCT06731868 | Safety and Efficacy of LPM3770164 Sustained-release Tablets in Patients With Tardive Dyskinesia | Luye Pharma Group Ltd. | Phase 1/2 | Recruiting | Tardive Dyskinesia (TD) | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06731868) |
| August 16, 2024 | NCT06556966 | A Study Assessing the Safety and Tolerability of LY03020 in Chinese Healthy Subjects | Luye Pharma Group Ltd. | Phase 1 | Completed | Schizophrenia, Alzheimer's Disease Psychosis | 66 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06556966) |
| July 11, 2024 | NCT06496048 | Lurbinectedin or in Combination with Irinotecan Versus Topotecan in Patients with Relapsed SCLC | Luye Pharma Group Ltd. | Phase 3 | Recruiting | Relapsed Small Cell Lung Cancer | 180 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06496048) |
| June 25, 2024 | NCT06474650 | Effect of Food on the Pharmacokinetics of LPM3770164 Sustained-release Tablets | Luye Pharma Group Ltd. | Phase 1 | Completed | Huntington Disease, Tardive Dyskinesia | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06474650) |
| June 21, 2024 | NCT06467409 | Phase II Clinical Trial to Evaluate the Efficacy and Safety of LPM3480392 Injection for Moderate to Severe Pain After Orthopedic Surgery | Luye Pharma Group Ltd. | Phase 2 | Unknown | Pain, Postoperative | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06467409) |
| May 23, 2024 | NCT06426485 | To Evaluate the Long-term Efficacy and Safety of Toludevenlafaxine Hydrochloride Sustained-release Tablets | Luye Pharma Group Ltd. | Phase 4 | Not yet recruiting | Major Depressive Disorder | 736 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06426485) |
| April 29, 2024 | NCT06388551 | A Phase 1, SAD Study to Evaluate the Safety and Tolerability of LY03017 | Luye Pharma Group Ltd. | Phase 1 | Unknown | Hallucinations and Delusions Associated With Alzheimer's Disease Psychosis, Hallucinations and Delusions Associated... | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06388551) |
| February 5, 2024 | NCT06240546 | First-in-Human Study of LPM6690176 in Patients With Advanced Solid Tumors. | Luye Pharma Group Ltd. | Phase 1 | Recruiting | Advanced Solid Tumor | 102 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06240546) |
| January 22, 2024 | NCT06216054 | Safety, Tolerability and Pharmacokinetic of Multiple-ascending Doses of LPM3770164 in Healthy Subjects | Luye Pharma Group Ltd. | Phase 1 | Completed | Tardive Dyskinesia, Huntington Disease | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06216054) |
| January 12, 2024 | NCT06204120 | Phase II Clinical Trial to Evaluate the Efficacy and Safety of LPM3480392 Injection for Moderate to Severe Pain After Abdominal Surgery | Luye Pharma Group Ltd. | Phase 2 | Completed | Pain, Postoperative | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06204120) |
| November 13, 2023 | NCT06128837 | Study of LY01610 in Patients With Recurrent Small Cell Lung Cancer | Luye Pharma Group Ltd. | Phase 3 | Recruiting | Relapsed Small Cell Lung Cancer | 686 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06128837) |
| October 24, 2023 | NCT06098599 | Comparing the Pharmacokinetic Profile of LY01612 and CAELYX® in Chinese Subjects With Advanced Breast Cancer | Luye Pharma Group Ltd. | Phase 1 | Completed | Advanced Breast Cancer | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06098599) |
| August 1, 2023 | NCT05970510 | A Study to Evaluate Efficacy and Safety of Toludesvenlafaxine Hydrochloride Sustained-release Tablets in Generalized Anxiety Disorder. | Luye Pharma Group Ltd. | Phase 3 | Completed | Generalized Anxiety Disorder | 555 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05970510) |
| May 19, 2023 | NCT05865925 | Safety, Tolerability, Pharmacokinetics (PK), and Primary Clinical Efficacy of LY01616 in Patients With Advanced Solid Tumors | Luye Pharma Group Ltd. | Phase 1/2 | Unknown | Advanced Solid Tumors | 78 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05865925) |
| May 17, 2023 | NCT05862974 | A Dose-escalation Study of LPM3480392 in Chinese Healthy Subjects | Luye Pharma Group Ltd. | Phase 1 | Completed | Healthy | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05862974) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 53 |
| Phase 1/2 | 3 |
| Phase 2 | 5 |
| Phase 3 | 12 |
| Phase 4 | 1 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 45 |
| Unknown | 14 |
| Not yet recruiting | 6 |
| Recruiting | 5 |
| Active not recruiting | 3 |
| Enrolling by invitation | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Parkinson Disease | 12 |
| Depressive Disorder, Major | 10 |
| Schizophrenia | 10 |
| Psychotic Disorders | 6 |
| Mood Disorders | 5 |
| Mental Disorders | 5 |
| Prostatic Neoplasms | 4 |
| Huntington Disease | 4 |
| Tardive Dyskinesia | 4 |
| Depressive Disorder | 3 |
| Small Cell Lung Carcinoma | 3 |
| Osteoporosis, Postmenopausal | 2 |
| Pain, Postoperative | 2 |
| Hallucinations | 2 |
| Schizophrenia Spectrum and Other Psychotic Disorders | 1 |
| Breast Neoplasms | 1 |
| Macular Degeneration | 1 |
| Recurrence | 1 |
| Colorectal Neoplasms | 1 |
| COVID-19 | 1 |
| Carcinoma, Non-Small-Cell Lung | 1 |
| Lipid Metabolism Disorders | 1 |
| Generalized Anxiety Disorder | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Turkish restaurants in the United States](https://specstream.ai/data/businesses/turkish-restaurants/united-states)
- [Hotel supply companies in the United States](https://specstream.ai/data/businesses/hotel-supply-companies/united-states)
- [Aircraft parts suppliers in the United States](https://specstream.ai/data/businesses/aircraft-parts-suppliers/united-states)
- [Life insurance agencies in the United States](https://specstream.ai/data/businesses/life-insurance-agencies/united-states)
- [B2B water treatment companies in the United States](https://specstream.ai/data/businesses/b2b-water-treatment-companies/united-states)
- [Occupational safety services in the United States](https://specstream.ai/data/businesses/occupational-safety-services/united-states)
